Harvard Medical School (HMS and HSDM)
The study aims at comparing two different approaches for vertical soft tissue augmentation at implant sites exhibiting soft tissue dehiscences: autogenous connective tissue graft vs acellular dermal matrix + enamel matrix derivative
The present randomized clinical trial aims at investigating two approaches (autogenous connective tissue graft vs acellular dermal matrix + enamel matrix derivative) when performed for vertical soft tissue augmentation at sites with peri-implant soft tissue dehiscences. Clinical, volumetric, ultrasonographic, and patient-reported outcomes will be evaluated at different time points up to 1 year.
Inclusion criteria: * Age ≥ 18 years * Periodontally and systemically healthy * Full-mouth plaque score and full-mouth bleeding score ≤ 20% (measured at four sites per tooth) * Presence of single functional dental implant in the anterior with a PSTD * Implants diagnosed as healthy (Berglundh et al., 2018) Exclusion criteria are: * Contraindications for surgery * Systemic condition (e.g. diabetes mellitus, HIV, cancer, etc) that could compromise wound healing * Patients pregnant or attempting to get pregnant (self-reported) * Untreated periodontitis * Untreated peri-implant mucositis or peri…
Vertical soft tissue augmentation with autogenous connective tissue graft (CTG)
Vertical soft tissue augmentation with acellular dermal matrix (ADM) and enamel matrix derivative (EMD)
Arctuva estimate
Verify or correct the compensation shown for this listing.